2002 / 11
PHARMAC documents that matched your search:
The number of people able to have subsidised access to a treatment for anaemia associated with kidney failure is set to nearly double following an agreement between PHARMAC and Roche Products.
Pharmaceutical Schedule - effective 1 December 2002
(224 pages, 1883 KB)
Almost 40,000 New Zealanders have access to better health as a result of pharmaceutical funding decisions made in the 2002 financial year. PHARMAC’s 2002 Annual Review, published today, highlights that new or or expanded access was provided to 24 different pharmaceuticals and produced savings worth more than $36 million in the 2002 financial year.
Major PHARMAC achievements in 2001-02 were: Providing new or wider access to 24 subsidised treatments, including those for raised cholesterol, multiple sclerosis, schizophrenia, epilepsy, arthritis and hay fever under cost-neutral and/or financially sustainable arrangements. Containing pharmaceutical expenditure growth by successfully negotiating savings worth approximately $36.8 million...
New Zealand will become one of the first countries in the world to fund imatinib mesylate (Glivec) as a first line treatment for chronic myeloid leukaemia, should the new therapy be approved for this use by the Ministry of Health. PHARMAC has agreed to fund Glivec for all patients for whom it is currently approved for use.